close 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse. Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Change languageEesti
Ülevaade
Kodu・Aktsiate loetelu・DBV Technologies SA
Search

DBV Technologies SA

Avatud

3.37 3.22

Osta

Hinna uuendus 31. dets 2025, 12:54 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.3449999999999998

Max

3.4

Põhinäitajad

By Trading Economics

Sissetulek

8.7M

-33M

Aktsiakasum

-0.1

Kasumimarginaal

-1,888.814

Töötajad

117

EBITDA

7.5M

-31M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+81.82% upside

Turustatistika

By TradingEconomics

Turukapital

-15M

421M

Eelmine avamishind

0.15

Eelmine sulgemishind

3.37

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

1.61 / 1.72 Toetus ja vastupanu

DBV Technologies SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. dets 2025, 22:20 UTC

Suurimad hinnamuutused turgudel

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

DJ

Loe

31. dets 2025, 17:31 UTC

Suurimad hinnamuutused turgudel

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

DJ

Loe

31. dets 2025, 16:30 UTC

Suurimad hinnamuutused turgudel

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

DJ

Loe

31. dets 2025, 15:19 UTC

Suurimad hinnamuutused turgudel

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

DJ

Loe

31. dets 2025, 15:17 UTC

Suurimad hinnamuutused turgudel

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

DJ

Loe

31. dets 2025, 14:37 UTC

Suurimad hinnamuutused turgudel

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

DJ

Loe

31. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Loe

31. dets 2025, 21:13 UTC

Omandamised, ülevõtmised, äriostud

10 People to Watch in Wealth Management in 2026 -- Barrons.com

DJ

Loe

31. dets 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

DJ

Loe

31. dets 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

DJ

Loe

31. dets 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

DJ

Loe

31. dets 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

DJ

Loe

31. dets 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

31. dets 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

DJ

Loe

31. dets 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

DJ

Loe

31. dets 2025, 17:16 UTC

Suurimad hinnamuutused turgudel

OwlTing Climbs on Launch of $10M Stock-Buyback Program

DJ

Loe

31. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

DJ

Loe

31. dets 2025, 17:00 UTC

Omandamised, ülevõtmised, äriostud

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

DJ

Loe

31. dets 2025, 15:57 UTC

Omandamised, ülevõtmised, äriostud

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

DJ

Loe

31. dets 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

DJ

Loe

31. dets 2025, 15:02 UTC

Suurimad hinnamuutused turgudel

Nike Shares Rise After CEO Hill Buys $1M of Shares

DJ

Loe

31. dets 2025, 14:40 UTC

Omandamised, ülevõtmised, äriostud

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

DJ

Loe

31. dets 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

DJ

Loe

31. dets 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

DJ

Loe

31. dets 2025, 13:01 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

DJ

Loe

31. dets 2025, 11:10 UTC

Market Talk

Copper Remains in Touching Distance of Record Highs -- Market Talk

DJ

Loe

31. dets 2025, 10:46 UTC

Market Talk

Euro on Track For Strong Annual Performance -- Market Talk

DJ

Loe

31. dets 2025, 10:25 UTC

Market Talk

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

DJ

Loe

31. dets 2025, 10:23 UTC

Market Talk

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

DJ

Loe

31. dets 2025, 09:33 UTC

Market Talk

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

DJ

Loe

DBV Technologies SA Prognoos

Hinnasiht

By TipRanks

81.82% tõus

12 kuu keskmine prognoos

Keskmine 6 EUR  81.82%

Kõrge 6 EUR

Madal 6 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi DBV Technologies SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

1

Osta

0

Hoia

0

Müü

Põhineb 1 analüütiku instrumendi DBV Technologies SA aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.61 / 1.72Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Bullish Evidence

Bullish events outweigh bearish events.

Pikk perspektiiv

Bullish Evidence

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest DBV Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
help-icon Live chat